top of page
  • Dr. J. James Frost

Therapeutics + Diagnostics = Theranostics

Updated: May 10

Personalized medicine is now fully realized by clinical molecular theranostics: the use of molecular imaging diagnostics to direct therapy with targeted cancer-ablative radioisotopes. From I-131 MIBG in children to somatostatin receptor-directed radiotherapy to the most recent PSMA, CXCR4 and other agents, Dr. J. James Frost has been involved from the conceptual to the clinical stages since his earliest work at Johns Hopkins. In addition, Dr. Frost’s early original research on the energetic effects of decaying radioisotopes and in nuclear and radiochemistry further demonstrate his broad knowledge needed to advance new theranostic agents.

Molecular theranostic agents have their greatest use in cancer diagnosis and radiotherapy. A key consideration at the therapy stage is correctly determining the radioactive treatment dose for effective cancer cell killing while avoiding radiation side effects. Recent advances in the use of PET and SPECT imaging for therapy dose determination is helping solve this problem. Outcomes must be quantified by RESIST and PERCIST criteria and by qualification of the diagnostic tracer uptake. BioMolecular Imaging has the needed knowledge and experience in all the required areas from dosimetry to imaging physics to expert image reads.

About BioMolecular Imaging

BioMolecular Imaging (BMI Consultants) is a molecular imaging and clinical trial consultancy owned and operated by Dr. J. James Frost M.D./Ph.D out of Baltimore Maryland. BMI has been involved with clinical, therapeutic & diagnostic imaging focused on Oncology, Brain, Biomarkers, Cardiology and Central Image Interpretations for over 20 years.

To learn more about BioMolecular Imaging, please visit or connect with:

Copyright © 2022 BioMolecular Imaging

BioMolecular Imaging is a registered trademark of BioMolecular Imaging D.B.A. BMI Consultants


bottom of page